Cytogen Quadramet Promotions Cited In FDA Ad Division Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
A radio ad, website and patient video for the cancer pain therapy overpromise benefits and minimize risk to “a very sick and vulnerable population,” FDA says. The warning letter follows a 2001 “untitled” letter for Quadramet that also objected to unsubstantiated efficacy claims.